IMUC

ImmunoCellular Therapeutics, Ltd.
IMUC

Overview Fund Activity
Delisted

IMUC was delisted on the 16th of October, 2018.

Back to rankings

34 hedge funds and large institutions have $3.35M invested in ImmunoCellular Therapeutics, Ltd. in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
34
Holders Change
+6
Holders Change %
+21.43%
% of All Funds
0.91%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
5
Reduced
6
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
B
1
Bailard
California
$653K
2
Citadel Advisors
2
Citadel Advisors
Florida
$37K
3
Renaissance Technologies
3
Renaissance Technologies
New York
$428K
4
GC
4
Guggenheim Capital
Illinois
$11K
5
RJA
5
Raymond James & Associates
Florida
$4K

Top Sellers

1
SM
1
Sabby Management
Florida
$1.28M
2
VKH
2
Virtu KCG Holdings
New York
$10K
3
GF
3
Gerstein Fisher
New York
$0
4
Vanguard Group
4
Vanguard Group
Pennsylvania
$742K
5
Citigroup
5
Citigroup
New York
$6K
Name Holding Trade Value Shares
Change 		Shares
Change %
Geode Capital Management
26
Geode Capital Management
Massachusetts
$127 – – –
GF
27
Gerstein Fisher
New York
– -$5K -325 Closed
TRCT
28
Tower Research Capital (TRC)
New York
– -$1K -45 Closed
1
2